Navigation Links
Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008

SAN FRANCISCO, Nov. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2008 progress and provide a general business update on Monday, November 10, 2008, at 4:30 p.m. Eastern time. A financial results press release for the third quarter ended September 30, 2008 will be released after markets close on November 10, 2008.

Interested parties may call 877-340-7912 from the U.S. or +1-719-325-4872 internationally. Individuals interested in listening to the live call via webcast may do so by visiting A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Medivation Announces Senior Management Promotions
5. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
11. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
Post Your Comments:
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care hub ... northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. , ... cell medicine to patients from around the world. , The clinics will be headed by ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
(Date:11/30/2015)... 2015  Culprits beware, a University at Albany ... Halámek, is taking crime scene fingerprint identification to ... -->   --> ... --> --> Halámek and his ... straightforward concept for identifying whether a culprit is ...
(Date:11/30/2015)... , Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" ... Norman C.W. Wong to its Board of Directors ... to Zenith with a wealth of experience as co-founder of ... biology. --> --> Dr. ... Epigenetics, board of directors. Zenith,s long standing expertise in epigenetics ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
Breaking Biology News(10 mins):